Oncología (médica)

A continuación se enumeran ensayos clínicos actuales.

Filtrar esta lista de estudios según la ubicación, el estado del estudio y más.

1. AZD0486 As Monotherapy In Participants With Relapsed/Refractory (R/R) B-cell NHL

   Rochester, Minn.

   This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of AZD0486 monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module 2 for DLBCL.

2. Wearable Artificial InTelligence For Cardiac Function And Health Monitoring

   Rochester, Minn.

   The purpose of thist study is to find a cost effective CV surveillance of cancer survivors over long periods of time to prevent the risk of progression of HF and related morbidity and mortality. Mobile device-based AI-ECG can reliably detect cardiac dysfunction in lymphoma and sarcoma survivors  and smart watch based surveillance for cardiotoxicity is feasible and reliable.

3. ROF2181

   Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   Currently, only a few international institutions use CIRT to treat pelvic bone sarcomas. Accordingly, data evaluating the potential differences in oncological outcomes, toxicities, and functional outcomes between CIRT and the more readily accessible local therapies of surgery and PT is scarce. For this reason, we propose conducting a prospective comparative effectiveness study evaluating functional outcomes, toxicities, and local control in patients with pelvic bone sarcomas treated with surgery, PT, and CIRT.

4. A Study To Evaluate EAA181 To Treat Newly-diagnosed Multiple Myeloma

   La Crosse, Wis., Rochester, Minn.

   The primary purpose of this study is to determine if bortezomib, daratumumab, lenalidomide and dexamethasone (Btz-DRd) consolidation followed by daratumumab and lenalidomide (DR) maintenance after standard induction therapy with daratumumab, lenalidomide and dexamethasone (DRd) results in superior overall survival compared to DRd consolidation followed by DR maintenance, in MRD positive patients.

5. Reduced Dose Hypofractionated Radiotherapy For Indolent Non-hodgkin Lymphoma

   Mankato, Minn., Rochester, Minn., Eau Claire, Wis., Jacksonville, Fla., La Crosse, Wis., Albert Lea, Minn., Scottsdale/Phoenix, Ariz.

   The purpose of thisstudy is to evaluate reduction of radiotherapy dose for patients with indolent NHL by conducting a prospective randomized phase 2 study comparing reduced dose hypofractionated ISRT of 9 Gy delivered over 3 fractions (BED 12 Gy) to standard of care 24 Gy delivered over 12 fractions (BED 29Gy), while simultaneously evaluating prognostic value of pre-radiation functional imaging parameters and molecular markers to predict treatment response and failure.